Cancer Treatment Type

Among AYA cancer survivors, gynaecological follow-up compliance varied significantly by treatment type, with surgery-alone patients showing the highest compliance (26.4%) and systemic-treatment-alone patients showing the lowest (17.4%). The lower gynaecological follow-up compliance in the systemic treatment group may reflect treatment burden discouraging further medical engagement, or an intensive oncological surveillance schedule crowding out preventive gynaecological care. Survivors who received systemic treatment are a priority subgroup for improved gynaecological follow-up given both their lowest compliance rates and the immunosuppression-related HPV and cervical neoplasia risks associated with their treatment.